Significant liver fibrosis

1. Cardiovascular-kidney-metabolic syndrome was not clearly linked with significant liver fibrosis in humans (CKM stages 1-4).

   “whereas no significant association was observed with significant fibrosis”

   HumansCKM stages 1-4n = 3,084

   Association of cardiovascular-kidney-metabolic syndrome stages with MASLD prevalence and liver fibrosis severity: evidence from traditional and machine learning approaches

   European journal of medical research·Feb 14, 2026

1. Diabetic macrovascular disease is associated with significant liver fibrosis in humans (OR 0.582).

   “Diabetic macrovascular disease showed an inverse association (OR = 0.582) that should not be interpreted as protective.”

   Humanstype 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease; association should not be interpreted as protectivelivern = 1,355

   Factors associated with significant liver fibrosis in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: a single-center retrospective study

   Frontiers in endocrinology·Oct 30, 2026

More on Diabetic macrovascular disease

1. Glinides are associated with significant liver fibrosis in humans (OR 2.524).

   “glinide use was positively associated (OR = 2.524)”

   Humanstype 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease; exploratory association with unavailable treatment timing relative to VCTElivern = 1,355

   Factors associated with significant liver fibrosis in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: a single-center retrospective study

   Frontiers in endocrinology·Oct 30, 2026

More on Glinides

1. SGLT2 inhibitors are associated with significant liver fibrosis in humans (OR 0.618).

   “SGLT-2 inhibitor use was inversely associated (OR = 0.618)”

   Humanstype 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease; exploratory association with unavailable treatment timing relative to VCTElivern = 1,355

   Factors associated with significant liver fibrosis in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: a single-center retrospective study

   Frontiers in endocrinology·Oct 30, 2026

More on SGLT2 inhibitors

1. Hyperuricemia is associated with significant liver fibrosis in humans (type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease) (OR 1.345).

   “hyperuricemia (OR = 1.345) were positively associated with significant fibrosis.”

   Humanstype 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver diseaselivern = 1,355

   Factors associated with significant liver fibrosis in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: a single-center retrospective study

   Frontiers in endocrinology·Oct 30, 2026

More on Hyperuricemia

1. CAP grade is associated with significant liver fibrosis in humans (type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease) (S1: OR 1.808; S2: OR 2.597; S3: OR 2.709).

   “Age, CAP grade, transaminase levels, GGT, and hyperuricemia were associated with significant fibrosis in patients with T2DM and MASLD.”

   Humanstype 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver diseaselivern = 1,355

   Factors associated with significant liver fibrosis in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: a single-center retrospective study

   Frontiers in endocrinology·Oct 30, 2026

More on CAP grade

1. Age is associated with significant liver fibrosis in humans (type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease) (OR 1.036).

   “Age (OR = 1.036), CAP grade (S1: OR = 1.808; S2: OR = 2.597; S3: OR = 2.709), AST (OR = 1.025), GGT (OR = 1.006), and hyperuricemia (OR = 1.345) were positively associated with significant fibrosis.”

   Humanstype 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver diseaselivern = 1,355

   Factors associated with significant liver fibrosis in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: a single-center retrospective study

   Frontiers in endocrinology·Oct 30, 2026

1. Sarcopenia is associated with significant liver fibrosis in humans (MASLD; adjusted for age, sex, body mass index, and diabetes) (Adjusted OR 2.03, 95% CI 1.10-3.77).

   “sarcopenia remained statistically associated with significant fibrosis (adjusted odds ratio (OR) 2.03, 95% CI 1.10-3.77; p = 0.024).”

   HumansMASLD; adjusted for age, sex, body mass index, and diabeteslivern = 276

   Frequency and Clinical Correlates of Sarcopenia in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease

   Cureus·Sep 19, 2026

More on Sarcopenia